Rethinking Clinical Trials

FEBRUARY 14, 2024

DCP developed an EHR-based workflows and integrated workflows within the local VA primary care setting. DCP developed 3 electronic workflows with 6 major configurations including applications needed outside of the EHR system. DCP developed a patient tracking tool that nurses could use to make sure patients got through each step.

Clinical Trials 152

Clinical Trials Clinical Trials Cardiology Trials 152

Drug Discovery World

DECEMBER 20, 2023

The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines.

Clinical Research 52

Clinical Research Research Cardiology Dermatology 52

Velocity Clinical Research

NOVEMBER 21, 2023

“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

XTalks

AUGUST 4, 2022

Cardiovascular clinical trials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinical trials. The Diversity of the US Population.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

The Pharma Data

AUGUST 22, 2021

Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). The IDMC recommended that the trial be discontinued due to lack of efficacy. Data from the trial will be provided to inform ongoing research. CHAMPION-ALS.

Trials 52

Trials Clinical Trials Clinical Trials Cardiology 52

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of Senior Vice President, Clinical Development, BlueRock Therapeutics. “We

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

Drug Discovery World

MAY 3, 2023

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction. Vicore Pharma states that results from the trial are expected in Q4, 2023.

Cardiology 52

Cardiology Trials FDA Approval Drug Trials 52

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Velocity Clinical Research Velocity is the leading integrated site organization for clinical trials. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 30, 2021

Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. 1 It affects one in 30,000 live births in the US.

Trials 52

Trials Genetics Cardiology Medicine 52

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Trials 52

Trials Cardiology Containment Development 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee. In July, finerenone was approved under the name Kerendia® by the us (U.S.)

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 9, 2020

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial. Amgen looks in need of fresh home-grown revenues, but investors don’t think these will come from omecamtiv mecarbil, based on the findings of the phase 3 GALACTIC-HF trial.

Trials 52

Trials Drugs Development Marketing 52

Delveinsight

DECEMBER 29, 2020

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Audentes Therapeutics’ ASPIRO Trial Free to Proceed. Billion Myovant/ Pfizer Deal. mg) in the US and Canada.

Trials 52

Trials Drugs Hormones Radiology 52

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

ACRP blog

JANUARY 24, 2023

Bringing our visions for clinical research to life in local communities with little knowledge of the role and benefits of clinical trials initially proved more difficult than we expected,” says Kristen Gurnea, MPH, CCRC, ACRP-PM, Manager of Clinical Research, Renown Health. “We

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

APRIL 12, 2021

Hope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed after the drug failed to make an impact in a phase 3 trial. . On the plus side, there were no safety issues in the trial.

Cardiology 74

Cardiology Antibody Trials Drugs 74

The Pharma Data

NOVEMBER 8, 2021

Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA and top investigator of the FIDELIO-DKD trial. “ The cardiology ballot at Bayer formerly includes a number of products and several other composites in colorful stages of preclinical and clinical development.

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

pharmaphorum

JUNE 25, 2021

But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In Granowitz says that the most sobering statistic from the REDUCE-IT study actually comes from the control group. Think about that.

Cardiology 89

Cardiology Drugs Development Clinical Trials 89

Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. In most cases, the participant of a clinical trial benefits from taking part, which is of great importance, especially in oncological trials. and Europe.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

The Pharma Data

JUNE 28, 2021

The approval is based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020. Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. Vericiguat is being jointly developed with MSD (a tradename of Merck & Co.,

Cardiology 52

Cardiology Production Development Medicine 52

pharmaphorum

MAY 18, 2021

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+ Ongoing clinical trials.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 92

Clinical Trials Clinical Trials Life Science Clinical Research 92

XTalks

JULY 7, 2023

a Canadian biopharmaceutical firm specializing in cardiovascular therapies, recently reported positive results from a Phase III clinical trial of its leading candidate, etripamil nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals Inc., How Does Etripamil Nasal Spray Work?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

JUNE 1, 2021

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. Working out which are more likely to benefit from stem cell therapy is likely to be a key challenge for developers. An interim look at the results is due later this month.

Trials 138

Trials Development Licensing Licensing 138

The Pharma Data

AUGUST 30, 2021

This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC). The most severe form of COVID-19 is severe respiratory failure, which requires intubation and is associated with a high mortality rate.

Drugs 52

Drugs Cardiology Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 16, 2024

Originally developed by California-based CoTherix, the drug was first approved in 2004 for the treatment of pulmonary arterial hypertension (PAH) under the brand name Ventavis. People who have poor circulation and who don’t dress appropriately for the weather are at the highest risk of developing frostbite.

Cardiology 59

Cardiology Gene Therapy Drugs Branding 59

Delveinsight

AUGUST 4, 2020

Not long ago, the companies inked an oncology pact to develop and commercialize MorphoSys’ anti-CD19 antibody Monjuvi jointly. Siemens Healthineers, formed as a result of spin-off in 2018, plans to increase its presence in oncology, neurology as well as cardiology domain. Billion deal in a thirst to grow in the cancer market.

Cardiology 55

Cardiology Antibody FDA Approval Trials 55

Scienmag

JUNE 17, 2021

Tools for clinicians in point-of-care use UTICA, NY — More than 2 million coronary artery stents are implanted each year to help protect or restore normal blood flow to the heart, to treat patients suffering from angina or a heart attack due to coronary artery disease (CAD). While stents are highly effective and safe devices, […].

Research 72

Research Development Clinical Trials Clinical Trials 72

The Pharma Data

MARCH 13, 2022

(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Dermatology 52

Dermatology Cardiology Development Medicine 52

Drug Discovery World

JULY 31, 2023

Based in France, CellProthera is a small, regenerative cell therapy developer that specialises in cardiovascular diseases. To develop its therapy, CellProthera must first take blood from a patient and bring that through to manufacture. T his is the market CellProthera wants to enter.

Medicine 52

Medicine Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

MARCH 31, 2023

Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. The positive opinion is based on final data from the 52-week Phase III PANORAMA-HF trial – the largest pediatric heart failure study ever conducted – and extrapolation of adult heart failure data from the Phase III PARADIGM-HF trial to pediatric patients 3,4.

Medicine 75

Medicine Trials Cardiology Production 75

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 52

Clinical Trials Clinical Trials Life Science Clinical Research 52

pharmaphorum

AUGUST 13, 2020

As a consequence, people with the condition can develop cardiovascular disease very early, even in childhood in some cases, despite aggressive treatment with cholesterol-lowering drugs like statins and PCSK9 inhibitors.

Drugs 52

Drugs Antibody Sales Cardiology 52

Scienmag

OCTOBER 6, 2020

Three ongoing influenza vaccine cardiovascular outcomes trials could hold insights into testing novel interventions against COVID-19 Seasonal influenza vaccine development and mass production, as well as three international influenza vaccine cardiovascular outcomes trials currently underway, may inform future efforts targeted at developing and evaluating (..)

Vaccination 40

Vaccination Vaccine Trials Production 40

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98